Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells – PR Web

Asymmetrex President & CEOJames L. Sherley, M.D., Ph.D.

BOSTON (PRWEB) May 06, 2021

The President and CEO of Massachusetts stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., has a busy speaking schedule for May and June. He is scheduled to give presentations in three virtual conference forums.

The scheduled virtual conferences are Clinical Trials Supply USA 2021, May 11; 5th Annual MarketsandMarkets Bioprocessing and Biotherapeutics UK, EU & APAC 2021, May 20-21; and the International Society for Stem Cell Research 2021 Annual Meeting, June 21-26. In addition, though not giving a formal presentation, Asymmetrex is a Tier 3 member sponsor of the American Regenerative Manufacturing Institutes 2021 Virtual Spring Meeting in the Millyard, June 8-17.

CEO Sherley says, Determining the number or dosage of therapeutic stem cells, like hematopoietic stem cells and mesenchymal stem cells, is the common denominator unmet need for all these disciplines. Asymmetrexs first-in-kind kinetic stem cell (KSC) counting technology provides an effective solution to the decades old dilemma of there being no means to determine the stem cell dosage of stem cell treatments.

Sherley will be presenting the companys most recent improvements in its KSC counting technology. With initial introduction, KSC counting was verified to do what methods like flow cytometry and colon forming unit (CFU) testing were unable to do. KSC counting can distinguish tissue stem cells, which are curative, from committed progenitor cells, which are not. The first generation of KSC counting required several weeks to perform. A soon to be released newer version of the technology requires only a few days to perform and at greatly reduced cost.

Asymmetric is now initiating studies to validate the clinical impact of treating patients with stem cell treatments of known stem cell dosage. Sherley is confident that, Its basic medicine. Finally knowing the stem cell dosage of stem cell treatments must necessarily be better for patients.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The companys U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Share article on social media or email:

Read this article:

Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells - PR Web

Read more
BioRestorative Therapies Expanding its Cell Therapy Manufacturing Facility – Stockhouse

MELVILLE, N.Y., May 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company” or BioRestorative”) (OTC: BRTX ) , a life sciences company focused on stem cell-based therapies, today announced that it is initiating expansion of its Melville, New York based research laboratories to include capabilities for the clinical production of the Company’s pipeline of clinical and investigational cell therapy candidates.

We look forward to expanding our current research and development operations to include clinical manufacturing, a necessary step to initiate our Phase 2 clinical trial for our novel Disc/Spine program,” said Lance Alstodt, CEO of BioRestorative. The ability to control internal clinical grade cell manufacturing capacity is critical in order to support multiple product manufacturing for our two programs: BRTX -100 and our allogeneic ThermoStem ® metabolic program. Additionally, this capability will allow us to advance our proprietary technologies and begin first in man clinical studies with our collaborative clinical partners.”

The cGMP facility is anticipated to include process development space, ISO 7 cleanrooms, and state-of-the-art scientific equipment. As the manufacturing facility becomes fully operational, the Company expects to hire additional full-time employees. The new facility is being designed to provide cGMP manufacturing according to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations and guidelines to support clinical grade cell production.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ( http://www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC ): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem ® ): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT: Lance Alstodt (631) 760-8406 Email: ir@biorestorative.com

View post:

BioRestorative Therapies Expanding its Cell Therapy Manufacturing Facility - Stockhouse

Read more
The Adaptive Immune System: Cellular & Humoral Immunity – The Great Courses Daily News

By Barry C. Fox, M.D., University of WisconsinAntibodies are one of the main components of the adaptive immune system. (Image: Kateryna Kon/Shutterstock)The Concept of the Adaptive Immune System

The adaptive immune system is composed of highly specialized cells that adapt to and learn from prior invaders. This is a system that remembers, for example, that someone had measles as a child, and will protect the body for a lifetime against measles.

The adaptive system has two major branches, the cell-mediated system, and the antibody-mediated humoral system. Note that humor is an old word that describes body fluidslike lymph and blood.

Lymphocytes, one of the five types of white blood cells, carry out the immune responses in both branches of the adaptive system. Lymphocytes are divided into B-cells and T-cells.

Fetal primitive stem cells that continue to mature in the bone marrow become B-cells. Others complete their growth in the thymus and become T-cells. Importantly, each B- and T-cell is specific only for one antigen, hence, they can only bind to one particular molecular structure.

Note that antigen is short for antibody generator, and represents any foreign substance. Macrophages are another type of white blood cellwith macro meaning big, and phages meaning eater. They are present in essentially all tissues of the body and are critical in both innate and adaptive immunity.

This is a transcript from the video series An Introduction to Infectious Diseases. Watch it now, on The Great Courses Plus.

B-cells work in the humoral immune system to mount a very specific antigen response. B-cells can also inactivate viruses by neutralizing them before they can enter host cells. Some B-cells become memory cells, allowing a quicker, more specific immune response the next time the body encounters the same infection.

T-cells, on the other hand, are part of a cell-mediated immune response and can be divided further into T-helper cells and cytotoxic T-cells. In the case of HIV or human immunodeficiency virus, the virus replicates rapidly and destroys the T-helper cells, resulting in more infected than healthy cells.

Cytotoxic T-cells attempt to destroy the HIV virus, but over time, the bodys ability to fight off infection is severely depletedmaking people with HIV highly susceptible to infections. T-cells also activate B-cells, and they can destroy microbes that are inside cells. Some T-cells also transform into memory cells so that they will recognize an invader if it ever attacks again.

Learn more about tick-borne diseasesa public health menace.

Antibodies are the other major component of the humoral system. Antibodies are produced by B lymphocytes that have matured into plasma cells. They can perform several functions, including neutralizing bacterial toxins, binding to viruses to prevent entry into cells, and opsonization in which a coating of antibodies increases the effectiveness of neutrophils trying to engulf bacteria.

Antibodies are analogous to the pincers of insects and are generally Y-shaped. There are four major categories of antibodiesimmunoglobulins M, A, E, and G.

IgM is a very large protein that clears foreign substances from the bloodstream. IgM antibodies are part of the bodys general first line of defense against invaders.

IgA is found in the secretions of the saliva and mucous. An IgA provides a mucosal first line of defense.

IgE is involved in immediate allergic responses, and sometimes, parasitic infections. IgE combines with a special cell known as a mast cell to release a chemical called histamine, which leads to swelling.

Finally, the most important immunoglobulin is IgG. IgG antibodies are formed in response to specific invaders, and they usually last a lifetime. They do take 714 days to be produced.

Learn more about how vaccines save lives.

IgG antibodies are produced in response to vaccination, but the two-week delay explains why it cannot be used as an immediate treatment strategy for infection. However, during the Ebola outbreak, another use of antibodies was testedafter the treatment and cure of the first American who had Ebola, doctors used the antibodies from his blood as a way to treat other patients with the Ebola virus.

The antibodies were transfused into newly infected patients in a process called passive immunizationproviding immediate antibodies instead of waiting two weeks. A similar process is utilized after some tetanus exposures.

For those individuals who have unusually severe allergies, immunotherapy is also possible. This treatment involves the intentional introduction of foreign allergic antigensunder medical supervisionto decrease IgE and increase IgG and IgA production. The net result is an improvement in allergy symptoms.

Learn more about bioterrorism and how worried we should be.

When a child gets the live measles vaccine, what happens after vaccination? The vaccine with measles antigens stimulates B-cells to mature into either an antibody-secreting plasma cell (producing IgM and IgG antibodies) or memory B-cells.

This is also known as the primary immune response. The antibody levels will gradually decline once the threat is over, but the memory B-cells remain dormant and present in the lymphatic system.

If the individual contracts the measles virus again as an adult, similar to waking a bear out of hibernation, the cells will rapidlywithin hoursstart producing large amounts of measles-specific IgG antibodies. Antibodies will attach themselves to the virus before they can attack healthy body cells. The memory immune lymphocytes would also recognize a pathogenic germ and assist in its destruction.

The adaptive immune system consists of specialized cells that adapt to and learn from previous invaders. For instance, this system remembers that someone had measles when they were a child, and when/if the same virus attacks their body again, this system will protect them.

Antibodies are a major component of the humoral immune system. The four major categories of antibodies are IgM, IgA, IgE, and IgG, with each one having a different function. Ig is short for immunoglobulins.

IgE is a significant antibody in the adaptive immune system. IgE is involved in immediate allergic responses, and sometimes, parasitic infections. IgE combines with a special cell known as a mast cell to release a chemical called histamine, which leads to swelling.

Read more:

The Adaptive Immune System: Cellular & Humoral Immunity - The Great Courses Daily News

Read more
Stem cell therapy as a basis for the regenerative medicine – America Daily Post

Significant advances in the experimental embryology, cytology, molecular genetics and genetic engineering have led to the formation of a new field of biomedicine regenerative medicine. Regenerative medicine employs pluripotency of stem cells for restoration of diverse tissues and body structures. The approach is applied in oncology, orthopedics, neurology, cardiology, endocrinology, etc.

The role of stem cells

Discussions about the benefits or risks of stem cells application are now often debated. At first, stem cells have appeared to be an expensive panacea that can cure any disease. Other publications have discussed the adverse effects of stem cell therapy, such as the risk of cancer. Repeatedly conducted studies have proved that the risk of cancer is zero. Stem cell therapy in Germany uses only proven scientifically methods of regenerative medicine, in which the development of complications is almost impossible.

Stem cells are cells that are capable of differentiation and transformation into many other types of cells, for example, skin cells, liver cells, brain cells, etc. Stem cells are divided into the natural (embryonic and adult cells) and grown in the laboratory ones. Each of these types has properties and characteristics that are unique to this type.

Cellular technologies are already developing so actively that they have moved from the fundamental biological field to the field of regenerative medicine, which implements the achievements of science of the last decades into practical healthcare tools this is translational medicine. That is, these technologies are not becoming prospects for the near future, but rather well-recognized, repeatedly tested, reliable methods of treatment.

What tissues can stem cells be harvested from?

Currently, the greatest attention is given to the adults own mesenchymal cells. Work with this type of stem cells does not carry the chance of developing cancer in the patient. Stem cells can be taken from various body tissues, such as red bone marrow, cartilage or skin. Then they are concentrated by centrifugation. Further, stem cells can go through the incubation and induction stage to increase their number. In other cases, mesenchymal stem cells are introduced into a sore spot immediately after concentration.

A mandatory and necessary condition for the effectiveness of therapy is the targeted injection of stem cells suspension directly into the damaged tissue. The procedure usually goes virtually painless, thanks to the latest equipment. For these purposes, doctors often use ultrasound or X-ray navigation methods.

Is stem cell therapy effective in older people?

A significant problem of cell therapy based on the use of own stem and progenitor cells is a decrease in the regenerative potential of cells with age and in patients with severe chronic diseases, primarily diabetes mellitus. Many laboratories in the world are working to increase the therapeutic activity of cells with the help of special modifications at the genetics level. For this purpose the introduction of growth factor genes, cytokines, or signaling molecules into the cells is used.

The increased ability of transplant to produce biologically active substances, increasing their viability and survival after transplantation into damaged tissues is taken into account. Its main concept is the cure of the disease due to the regeneration of altered or damaged tissues or organs.

Is it possible to use stem cells in oncology treatment?

In German clinics, stem cell therapy is actively used for the treatment of cancer. It is especially effective in the treatment of solid tumors, this method is used as an additional option in the conventional cancer chemotherapy, radiation therapy or surgery.

This type of therapy is also applied in patients at the stage of remission in order to prevent relapse. Stem cells are also aimed at reducing side effects after chemotherapy and radiation therapy.

If you are interested in stem cell treatment and would like to receive it in Germany, please contact Booking Health. Booking Health specialists will provide comprehensive information regarding all your questions, select individual diagnostic or treatment programs for you. You will also receive assistance in all organizational aspects, such as visa issuing, booking tickets, transfer, selection of housing and so on. With the support of Booking Health, you can be sure that your stay in Germany will be as comfortable as possible.

See the rest here:

Stem cell therapy as a basis for the regenerative medicine - America Daily Post

Read more
DKMS-BMST Thalassemia Programmes Raising Hope For Thalassemia Patients In India – PR Newswire India

BENGALURU, India, May 8, 2021 /PRNewswire/ -- World Thalassemia Day is observed every year on 8th May to raise awareness on the growing burden of Thalassemia. Thalassemia is a genetic condition in which a defect in the protein hemoglobin reduces the transport capacity for oxygen in the blood. More than 10,000 children are born with this condition every year in India. Patients suffering from the disease can be cured with a stem cell transplant, ideally at an early age. The need for transplants in children is therefore extremely high.

Patrick Paul, CEO, DKMS BMST Foundation India, says, "It is our mission to support blood cancer, and other blood disorders such as Thalassemia patients in India, for which we have initiated DKMS-BMST Thalassemia programme. Under this programme, DKMS-BMST collaborates with local NGOs and transplantation clinics to organize camps where pediatric thalassemia patients and their siblings travelling from afar places in India to give buccal swab samples for HLA typing. Samples from the camps are analyzed in the DKMS laboratory based out of Germany and clinical matching reports of the same are provided. In cases where there is no matching sibling for a sick child, we also support unrelated donor searches for patients."

Through this programme, so far;over 4700 HLA typing have been facilitated by DKMS-BMST. In the year 2020, around 800 patients were able to find a matching donor and over 86 Thalassemia camps have been conducted since 2019 till date across India.

One of the Thalassemia survivors, 9-year-old girl Grishmitha, a resident of Kundapura, Karnataka was diagnosed with Thalassemia in 2014 and she received a stem cell transplant under Dr. Sunil Bhat at Narayana Health Bengaluru in 2017 through a DKMS donor. Her mother says, "All thanks to the donor that today my daughter is doing well. Currently she is in 3rd standard, fully recovered and is growing like any other child of her age."

Another Thalassemia survivor is a 12-year-old boy Bibek Singh from Ludhiana, Punjab. His father says, "My son was diagnosed with Thalassemia in 2010 and had to undergo blood transfusion every 15 days, until he found a matching donor through DKMS and underwent a stem cell transplant in 2018 under Dr. Joseph John at CMC Ludhiana. Bibek is doing well and has an active lifestyle now."

Dr. Sunil Bhat, Director and Clinical Lead, Pediatric Hematology, Oncology and Blood & Marrow Transplantation, Narayana Health, Bengaluru, said, "A blood stem cell transplant is the only curative intervention available for a transfusion free status with a normal life span for Thalassemia patients. Stem cell registries like DKMS-BMST enroll adult healthy unrelated donors who consent to donate their stem cells for transplant purpose. The registries are the nerve centers of whole unrelated donor transplant process that counsel donors, enroll donors, get their HLA typing done, facilitate search of the donors and later facilitate the stem cell collection and transplant. There is need to strengthen these registries and have maximum donor recruitments."

"Indian patients mainly require an Indian tissue match. This calls for increased awareness and need to encourage many more people in India to register as a potential blood stem cell donor," added Patrick.

To register as a potential blood stem cell donor please visit: http://www.dkms-bmst.org/register

DKMS BMST Foundation India is a part of DKMS: one of the largest international blood stem cell donor centers in the world. DKMS has facilitated around 90,000 second chances at life globally. DKMS-BMST at present has over 46,000 registered potential blood stem cell donors and has given second chances at life to 33 patients in India. This number will increase considerably over the years with the aim of finding a matching donor for every patient in need.

SOURCE DKMS BMST Foundation India

Original post:

DKMS-BMST Thalassemia Programmes Raising Hope For Thalassemia Patients In India - PR Newswire India

Read more
World Thalassemia Day 2021: Thalassemia, an inherited blood disorder, in Children – The Financial Express

Currently, COVID has caused great misfortune in the life of thalassemia patients.

By Dr Santanu Sen

Thalassemia is an inherited blood disorder that results in the body having less haemoglobin than normal. Haemoglobin in our red blood cells carries oxygen. Hence, Thalassemia causes severe anaemia, tiredness, fatigue, growth failure and patients need lifelong blood transfusions every 2-3 weeks to survive. They also need prolonged medical therapy to manage all the numerous complications that arise from the disease and from having frequent blood transfusions.

It is a genetic disease that occurs in children, where both the parents carry a single defective copy of the gene responsible for blood production. Though the parents themselves have no problems, 25% of children of such couples would inherit defective genes from both parents and become affected.

India, with about 100,000 patients, has one of the highest numbers of thalassemia patients in the world. And every year more than 10,000 children are born with thalassemia. It is seen in large numbers among certain communities, such as Sindhis and Punjabis from Northern India, Bhanushalis, Kutchis, Lohanas from Gujarat, Mahars, Neobuddhists, Kolis and Agris from Maharashtra, & Gowdas and Lingayats from Karnataka etc. where the carrier rate is extremely high.

Once a child is diagnosed to have thalassemia, they will need regular lifelong blood transfusions 2-3 weeks. They also need treatment to manage the disease and complications of blood transfusions, such as short stature, delayed puberty, growth failure, diabetes, and infections such as Hepatitis B & C, HIV, CMV etc. A lifelong therapy to control the iron overload that results from the repeated blood transfusions is also required. The overall quality of life for most children is very poor with lower life expectancy and frequent admissions. Most children do not have access to properly managed expert care and end up being under transfused and having to suffer from chronic ill health, multiple infections and significantly shortened life span. Less than 5-10% of these children born in India receive optimal treatment.

A stem cell transplantation (also known as a Bone Marrow transplant or BMT) is the only cure for thalassemia major. However, finding a suitable donor is still a major obstacle to curing these patients. An ideal donor for BMT is a brother or sister who does not have the disease and is also genetically completely matched to the patient. A special test called HLA typing is used to check if the patient and the possible donor is a full match. A second choice is a matched unrelated donor, if available from a stem cell registry. Though previously lacking, fortunately, India now has a good stem cell donor registry called Datri, where volunteer donors can register themselves and be a potential lifesaver when they are found to be a match for a patient with a fatal disease.

However, the vast majority of patients lack either a sibling or an unrelated donor. A recent ray of hope for them has been the successful use of Haploidentical donors. Here, a sibling or parent who may be a half match to the patient can be used as the donor for the transplant. This approach for Haploidentical transplants has been very successfully used in various blood cancers. A similar approach has given encouraging results for Thalassemia major patients with stable engraftment and a transfusion independent life with normal life expectancy. Another option for a cure is gene therapy whereby the patients own stem cells are genetically edited and transplanted back to the patient to restart the production of blood.

Currently, COVID has caused great misfortune in the life of thalassemia patients. With voluntary blood donations falling to an all-time low in the country due to the pandemic, blood banks are struggling to find suitable and adequate units, and patients are having to wait for a longer period without any available transfusions. In addition, many private thalassemia centres have also shut down over this period, leaving patients struggling to make alternate arrangements at the last moment. Thalassemia patients who contact COVID are doubly affected: firstly by the illness itself from the virus and secondly as most units will refuse admission to a positive patient for a transfusion. Though exact data is lacking, there are some indications that COVID itself might be more serious in thalassemia patients. Many BMT units have stopped transplants due to concerns over the risk of COVID in transplanted patients.

Prevention of thalassemia would be the ideal solution to the problem. This can be done by creating awareness amongst high-risk communities, telling them about the prevalence of the disease and the many difficulties in the management of this condition. Young adults in these communities need to be screened to identify those people who may not even know that they are a carrier for the disease. Haemoglobin electrophoresis is the confirmatory test to diagnose thalassemia minor or carrier status and such patients need to be counselled about the risk of the disease in their children if they should marry another carrier. All at-risk couples need to be counselled about the prenatal diagnosis to confirm the thalassemia status of the foetus, which can help to decide whether or not it is suitable to continue the pregnancy.

Hopefully, a multipronged strategy as detailed above can lead us to the age where no child should suffer from thalassemia.

(The author is Consultant, Paediatric Hematology, Oncology & Stem Cell Transplantation, Kokilaben Dhirubhai Ambani Hospital. The article is for informational purposes only. Please consult experts and medical professionals before starting any therapy or medication. Views expressed are personal and do not reflect the official position or policy of the Financial Express Online.)

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know markets Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

More here:

World Thalassemia Day 2021: Thalassemia, an inherited blood disorder, in Children - The Financial Express

Read more
Century Therapeutics Expands Board of Directors with Key Appointments – PRNewswire

PHILADELPHIA, May 5, 2021 /PRNewswire/ -- Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Joe Jimenez as Board Chair and Cynthia Butitta as a new Independent Director.

As former CEO of Novartis and current Co-Founder and Managing Partner of biotech venture firm Aditum Bio, Mr. Jimenez has extensive expertise in the biopharma industry driving innovation and leading companies at varying stages of development. Ms. Butitta is a veteran biotech executive specializing in corporate finance and strategic operations, most recently as the Chief Operating Officer and Chief Financial Officer of Kite Pharma.

"Joe Jimenez and Cindy Butitta bring decades of leadership and proven records of success in the pharmaceutical and biotech industries to the Century board," said Lalo Flores, Chief Executive Officer of Century Therapeutics. "Their expertise will be invaluable as we continue to grow Century into a premier cell therapy company that dramatically and positively transforms the lives of patients suffering from life-threatening cancers."

"During my time on Century's Board of Directors, I have been impressed by the company's strategic, vertically-integrated approach to overcoming many of the challenges associated with existing allogeneic cell therapies," said Mr. Jimenez. "The team's deep expertise in cell therapy and drug development, manufacturing, and commercialization uniquely positions them to lead the next phase of cell therapy and I am pleased to continue to support the company in my new role as board chair."

Mr. Jimenez joined Century's Board of Directors in 2020. He previously served as Chief Executive Officer of Novartis. Under his leadership, Novartis won FDA approval for use of their CAR T cell therapy, Kymriah, to treat B-cell acute lymphoblastic leukemia and developed one of the largest pipelines of self-originated drugs in the biopharma industry. Mr. Jimenez's strong commitment to R&D resulted in transformation of the company's portfolio to focus on innovative and patent-protected medicines. Mr. Jimenez is also a member of the Board of Directors of General Motors Company, The Procter & Gamble Company, and Graphite Bio. Mr. Jimenez earned his B.S. in economics from Stanford University and his M.B.A. in marketing from the University of California, Berkeley's Haas School of Business.

Ms. Butitta brings more than 25 years of experience informing corporate strategy and business development in the biotechnology and high technology sectors to the Century Board of Directors. Most recently, she served as the Chief Operating Officer and Chief Financial Officer of Kite Pharma where she was responsible for securing over $1 billion in capital and contributed to the extensive growth of the organization. Ms. Butitta was also critical in facilitating the company's acquisition by Gilead Sciences for approximately $11.9 billion in 2017. Prior to Kite Pharma, Ms. Butitta was the Senior Vice President and Chief Financial Officer of NextWave Pharmaceuticals until its acquisition by Pfizer in 2012. She has also held executive leadership roles at Telik, Inc., Connetics Corporation, and InSite Vision Inc. Ms. Butitta is currently an Independent Director at Olema Oncology, Autolus Ltd., and UroGen Pharma. She holds a B.S. in business and accounting from Edgewood College and received her M.B.A. in finance from the University of Wisconsin, Madison.

"Century's proprietary iPSC based allogeneic cell platform technology offers the potential to treat a broad range of cancers by exploiting the distinct biologies of both NK and T cells," said Ms. Butitta. "I'm honored to join the Board of such a forward-thinking company during this critical period of growth and look forward to working with my fellow board members to help progress the company's pipeline of revolutionary cell therapies through the clinic to patients in need."

About Century Therapeutics

Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. For more information, please visit http://www.centurytx.com.

SOURCE Century Therapeutics

https://www.centurytx.com/

More:

Century Therapeutics Expands Board of Directors with Key Appointments - PRNewswire

Read more
Stem Cell Therapy Market 2021 to Perceive Biggest Trend and Opportunity by 2027 The Manomet Current – The Manomet Current

The Global Stem Cell Therapy Market By Data Bridge Market Research provides a in-depth overview of the key aspects of the market. Stem Cell Therapy report can be mainly categorised into major areas which are market definition, market segmentation, competitive analysis and research methodology. This market research report comprises of key information about the industry, market segmentation, important facts and figures, expert opinions, and the latest developments across the globe. Market research studies conducted in this business report are very attentive for the businesses which help them with the better decision making and develop better strategies about production, marketing, sales and promotion. Regional estimates and forecasts & trend analysis for each country and region are also available in the study. market includes investigations based on the current scenarios, historical records, and future predictions. This report centers on the business status, presents volume, key market, product type, consumers, regions, and key players. Businesses can achieve practical and undergoing results that are driven by accurate and timely research.

Stem cell therapy market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 18.66 billion by 2027 growing with a CAGR of 9.25% in the above-mentioned forecast period. The growing awareness to therapeutic potency of stem cells in disease organization will help in driving the growth of the stem cell therapy market.

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-therapy-market&utm_source=AS&utm_medium=AS

Stem Cell Therapy Market Size Segment by Companies, this report covers:

Osiris Therapeutics, Inc MEDIPOST Co., Ltd Anterogen Co., Ltd Pharmicell Co., Ltd STEMCELL Technologies Inc Astellas Pharma Inc Cellular Engineering Technologies Inc BioTime Inc Takara Bio Inc U.S. Stem Cell, Inc BrainStorm Cell Therapeutics Inc Caladrius Biosciences, Inc Athersys

Market Segmentation Covered in the Report

By Technology (Cell Acquisition, Cell Production, Cryopreservation, Expansion and Sub-Culture)

By Product (Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells)

By Applications (Musculoskeletal Disorders, Wounds, Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, Other Applications)

By End Users (Therapeutic Companies, Cell And Tissues Banks, Tools And Reagent Companies, Service Compan

By Region

North America (U.S., Canada, Mexico)

Asia Pacific (India, China, Japan, South Korea, ASEAN, Rest of Asia Pacific)

Europe (Italy, Germany, France, Spain, Central & Eastern Europe, Rest of Europe)

Middle East & Africa (GCC, Turkey, Rest of the Middle East & Africa)

South America (Brazil, Argentina, Rest of South America)

Browse For Full Report:https://www.databridgemarketresearch.com/reports/global-stem-cell-therapy-market?utm_source=AS&utm_medium=AS

Research Methodology:

Years considered for the study are:

Historical year 2010-2019

Disreputable year 2020

Estimate period 2021 to 2028

Impact of COVID-19 on the Market

The COVID-19 epidemic has had an effect on many characteristics, such as travel bans; flight cancellations; quarantines; limited all indoor events proclaimed emergency in many countries; unpredictability of the stock market; major supply chain slowdown; declining economic assurance, and in sighted insecurity about the future. By generating supply chain turmoil, by directly influencing production and demand, and by having an economic impact on businesses and commercial markets, COVID-19 will influence the global economy.

To receive extensive list of important regions, ask for TOC here @https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-therapy-market&utm_source=AS&utm_medium=AS

Further Key Aspects Of The Report Indicate:

Enquire Here for, Report Enquiry, Discount and Customization: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-therapy-market&utm_source=AS&utm_medium=AS

Customization of the Report:This Stem Cell Therapy report can be customized as per your needs for additional data up to 10+ companies, Regional and geographical countries or 40 analyst hours.

The Stem Cell Therapy report covers all the market shares and approaches of the major competitors or the key market players. Such highlights about competitive landscape plays very important role in deciding about the enhancements required in the product already in the market or the future product. The report also performs systemic analysis of growth trends and future prospects. Besides, this market report contains an extensive evaluation of the markets, growth prospects and restrictions. An influential Stem Cell Therapy market report offers an utter background analysis of the Stem Cell Therapy industry along with an assessment of the parental Stem Cell Therapy market. It is an essential document for every market enthusiast, policymaker, investor, and market player.

Global Stem Cell Therapy Market Scope and Market Size

Based on type, the stem cell therapy market is segmented into allogeneic stem cell therapy and autologous stem cell therapy On the basis of technology, the stem cell therapy market is segmented into cell acquisition, cell production, cryopreservation and expansion and sub-culture On the basis of product, the stem cell therapy market is segmented into adult stem cells, human embryonic stem cells and induced pluripotent stem cells Based on application, the stem cell therapy market is segmented into musculoskeletal disorders, wounds, injuries, cardiovascular diseases, surgeries, gastrointestinal diseases and other applications

Competitive Landscape and Stem Cell Therapy Market Share Analysis

The major players covered in the stem cell therapy market report are Osiris Therapeutics, Inc., MEDIPOST Co., Ltd., Anterogen Co., Ltd., Pharmicell Co., Ltd., STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Caladrius Biosciences, Inc., Athersys., Cytori Therapeutics, Inc., Fate Therapeutics Inc., Pluristem Therapeutics Inc., Thermo Fisher Scientific., Vericel Corporation., ViaCyte, Inc, AbbVie, Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, Aastrom Biosciences, Inc., Advanced Cell Technology

Key Influence of the Stem Cell Therapy Market:

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:-corporatesales@databridgemarketresearch.com

Visit link:

Stem Cell Therapy Market 2021 to Perceive Biggest Trend and Opportunity by 2027 The Manomet Current - The Manomet Current

Read more
Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells – WFMZ Allentown

BOSTON, May 6, 2021 /PRNewswire-PRWeb/ --The President and CEO of Massachusetts stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., has a busy speaking schedule for May and June. He is scheduled to give presentations in three virtual conference forums.

The scheduled virtual conferences are Clinical Trials Supply USA 2021, May 11; 5th Annual MarketsandMarkets Bioprocessing and Biotherapeutics UK, EU & APAC 2021, May 20-21; and the International Society for Stem Cell Research 2021 Annual Meeting, June 21-26. In addition, though not giving a formal presentation, Asymmetrex is a Tier 3 member sponsor of the American Regenerative Manufacturing Institute's 2021 Virtual Spring Meeting in the Millyard, June 8-17.

CEO Sherley says, "Determining the number or dosage of therapeutic stem cells, like hematopoietic stem cells and mesenchymal stem cells, is the common denominator unmet need for all these disciplines." Asymmetrex's first-in-kind kinetic stem cell (KSC) counting technology provides an effective solution to the decades old dilemma of there being no means to determine the stem cell dosage of stem cell treatments.

Sherley will be presenting the company's most recent improvements in its KSC counting technology. With initial introduction, KSC counting was verified to do what methods like flow cytometry and colon forming unit (CFU) testing were unable to do. KSC counting can distinguish tissue stem cells, which are curative, from committed progenitor cells, which are not. The first generation of KSC counting required several weeks to perform. A soon to be released newer version of the technology requires only a few days to perform and at greatly reduced cost.

Asymmetric is now initiating studies to validate the clinical impact of treating patients with stem cell treatments of known stem cell dosage. Sherley is confident that, "It's basic medicine. Finally knowing the stem cell dosage of stem cell treatments must necessarily be better for patients."

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company's U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Media Contact

James L Sherley, Asymmetrex, LLC, 6179906819, jsherley@asymmetrex.com

Twitter, LinkedIn, Facebook

SOURCE Asymmetrex, LLC

Go here to read the rest:

Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells - WFMZ Allentown

Read more
The Canine Stem Cell Therapy Market To Witness A Growth-Wise Disruption Between 2026 – Industry Today

The Canine Stem Cell Therapy Market report by PersistenceMarketResearch throws light on the fact that the healthcare industry is more towards value-based care and continuous improvements based on the feedback. The mainstreaming of this practice is increasing all through. As such, the healthcare providers could make way for customized, lasting, and effective solutions to render utmost care to patients.

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/15550

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness aCAGR of 4.2%during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation ofUS$ 218.2 Mnby the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Top Reports of Persistence Market Research :-

Active Pharmaceutical Ingredient Market Persistence Market Research predicts that the globalactive pharmaceutical ingredients marketto exhibit a CAGR above 4% over the forecast period (2021-2031).

Opioids MarketAccording to the revised report published by Persistence Market Research, the globalopioids marketvalued at US$ 40.5 Bn in 2020, and is predicted to expand at a CAGR of 3% over the forecast period (20212031).

Autogenous Vaccines MarketAccording to a revised report published by Persistence Market Research, theautogenous vaccines marketwas valued over US$ 116 Mn in 2020, and is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031).

About us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact us:

Persistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsite https://www.persistencemarketresearch.com

Original post:

The Canine Stem Cell Therapy Market To Witness A Growth-Wise Disruption Between 2026 - Industry Today

Read more